<drug type="small molecule" created="2017-02-27" updated="2017-03-09">
  <drugbank-id primary="true">DB13170</drugbank-id>
  <name>Plecanatide</name>
  <description>Plecanatide is a drug approved in January 2017 by the FDA for the treatment of chronic idiopathic constipation (CIC). It should not be used in children less than six years of age, and should be avoided in patients six years to 18 years of age</description>
  <cas-number>467426-54-6</cas-number>
  <unii>7IK8Z952OK</unii>
  <average-mass>1681.89</average-mass>
  <monoisotopic-mass>1680.625200237</monoisotopic-mass>
  <state>solid</state>
  <groups>
    <group>approved</group>
  </groups>
  <general-references>
    <articles>
      <article>
        <pubmed-id>26016701</pubmed-id>
        <citation>Thomas RH, Luthin DR: Current and emerging treatments for irritable bowel syndrome with constipation and chronic idiopathic constipation: focus on prosecretory agents. Pharmacotherapy. 2015 Jun;35(6):613-30. doi: 10.1002/phar.1594. Epub 2015 May 27.</citation>
      </article>
    </articles>
    <textbooks/>
    <links>
      <link>
        <title>Drug Information</title>
        <url>https://www.drugs.com/history/trulance.html</url>
      </link>
      <link>
        <title>Medscape</title>
        <url>http://reference.medscape.com/drug/trulance-pecanatide-1000108#10</url>
      </link>
      <link>
        <title>FDA label</title>
        <url>http://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208745lbl.pdf</url>
      </link>
    </links>
  </general-references>
  <synthesis-reference/>
  <indication>Plecanatide stimulates intestinal fluid secretions in the gastrointestinal tract to support regular bowel function. Plecanatide, taken orally once daily, works locally in the upper GI tract to stimulate secretion of intestinal fluid and support regular bowel function.</indication>
  <pharmacodynamics>Food Effect Subjects who received either a low-fat, low calorie (LF-LC) meal or a high fat, high calorie (HF-HC) meal reported looser stools than fasted subjects up to 24 hours after a single dose of 9 mg (3 times the recommended dose). In clinical studies, Plecanatide was administered with or without food.</pharmacodynamics>
  <mechanism-of-action>Guanylate cyclase C (GC-C) agonist&#13;
Plecanatide and its active metabolite bind to GC-C and act locally on the luminal surface of intestinal epithelial cells; GC-C activation leads to increased cyclic guanosine monophosphate (cGMP), which, in turn, stimulates secretion of chloride and bicarbonate into the intestinal lumen, mainly by activation of the cystic fibrosis transmembrane conductance regulator (CFTR) ion channel, resulting in increased intestinal fluid and accelerated transit.&#13;
 In animal models, plecanatide has been shown to increase fluid secretion into the gastrointestinal (GI) tract, accelerate intestinal transit, and cause changes in stool consistency.&#13;
In an animal model of visceral pain, plecanatide reduced abdominal muscle contractions, a measure of intestinal pain. The mechanism has not been studied. </mechanism-of-action>
  <toxicity>Single oral doses of plecanatide at 0.5 mg/kg and 10 mg/kg caused mortality in young juvenile mice on postnatal days 7 and 14, respectively (human age equivalent of approximately 1 month to less than 2 years). </toxicity>
  <metabolism>Plecanatide is metabolized in the GI tract to an active metabolite by loss of the terminal leucine moiety. Both plecanatide and the metabolite are proteolytically degraded within the intestinal lumen to smaller peptides and naturally occurring amino acids. </metabolism>
  <absorption>Plecanatide is minimally absorbed with negligible systemic availability following oral administration.&#13;
Concentrations of plecanatide and its active metabolite in plasma are below the limit of quantitation after an oral dose of 3 mg. Therefore, standard pharmacokinetic parameters such as AUC, maximum concentration (Cmax), and half-life (t½) cannot be calculated. </absorption>
  <half-life> half-life (t½) cannot be calculated due to negligible systemic absorbance</half-life>
  <protein-binding>Plecanatide exhibits little to no binding to human serum albumin or human α-1-acid glycoprotein. </protein-binding>
  <route-of-elimination>No excretion studies have been conducted in humans. Plecanatide and its active metabolite are not measurable in plasma following administration of the recommended clinical doses. </route-of-elimination>
  <volume-of-distribution>Concentrations of plecanatide and its active metabolite in plasma are below the limit of quantitation after an oral dose of 3 mg. Therefore, the volume of distribution can not be calculated.</volume-of-distribution>
  <clearance>No excretion studies have been conducted in humans. </clearance>
  <classification>
    <description>This compound belongs to the class of organic compounds known as polypeptides. These are peptides containing ten or more amino acid residues.</description>
    <direct-parent>Polypeptides</direct-parent>
    <kingdom>Organic compounds</kingdom>
    <superclass>Organic Polymers</superclass>
    <class>Polypeptides</class>
    <subclass/>
    <alternative-parent>Alpha amino acid amides</alternative-parent>
    <alternative-parent>Amino acids</alternative-parent>
    <alternative-parent>Asparagine and derivatives</alternative-parent>
    <alternative-parent>Aspartic acid and derivatives</alternative-parent>
    <alternative-parent>Azacyclic compounds</alternative-parent>
    <alternative-parent>Carbonyl compounds</alternative-parent>
    <alternative-parent>Carboxylic acids</alternative-parent>
    <alternative-parent>Cyclic peptides</alternative-parent>
    <alternative-parent>Glutamic acid and derivatives</alternative-parent>
    <alternative-parent>Hydrocarbon derivatives</alternative-parent>
    <alternative-parent>Lactams</alternative-parent>
    <alternative-parent>Leucine and derivatives</alternative-parent>
    <alternative-parent>Macrolactams</alternative-parent>
    <alternative-parent>Monoalkylamines</alternative-parent>
    <alternative-parent>N-acyl amines</alternative-parent>
    <alternative-parent>N-acyl-L-alpha-amino acids</alternative-parent>
    <alternative-parent>Organic disulfides</alternative-parent>
    <alternative-parent>Organic oxides</alternative-parent>
    <alternative-parent>Primary carboxylic acid amides</alternative-parent>
    <alternative-parent>Secondary alcohols</alternative-parent>
    <alternative-parent>Secondary carboxylic acid amides</alternative-parent>
    <alternative-parent>Tetracarboxylic acids and derivatives</alternative-parent>
    <substituent>Alcohol</substituent>
    <substituent>Aliphatic heteropolycyclic compound</substituent>
    <substituent>Alpha-amino acid amide</substituent>
    <substituent>Alpha-amino acid or derivatives</substituent>
    <substituent>Amine</substituent>
    <substituent>Amino acid</substituent>
    <substituent>Amino acid or derivatives</substituent>
    <substituent>Asparagine or derivatives</substituent>
    <substituent>Aspartic acid or derivatives</substituent>
    <substituent>Azacycle</substituent>
    <substituent>Carbonyl group</substituent>
    <substituent>Carboxamide group</substituent>
    <substituent>Carboxylic acid</substituent>
    <substituent>Carboxylic acid derivative</substituent>
    <substituent>Cyclic alpha peptide</substituent>
    <substituent>Fatty acyl</substituent>
    <substituent>Fatty amide</substituent>
    <substituent>Glutamic acid or derivatives</substituent>
    <substituent>Hydrocarbon derivative</substituent>
    <substituent>Lactam</substituent>
    <substituent>Leucine or derivatives</substituent>
    <substituent>Macrolactam</substituent>
    <substituent>N-acyl-alpha amino acid or derivatives</substituent>
    <substituent>N-acyl-alpha-amino acid</substituent>
    <substituent>N-acyl-amine</substituent>
    <substituent>N-acyl-l-alpha-amino acid</substituent>
    <substituent>N-substituted-alpha-amino acid</substituent>
    <substituent>Organic disulfide</substituent>
    <substituent>Organic nitrogen compound</substituent>
    <substituent>Organic oxide</substituent>
    <substituent>Organic oxygen compound</substituent>
    <substituent>Organoheterocyclic compound</substituent>
    <substituent>Organonitrogen compound</substituent>
    <substituent>Organooxygen compound</substituent>
    <substituent>Polypeptide</substituent>
    <substituent>Primary aliphatic amine</substituent>
    <substituent>Primary amine</substituent>
    <substituent>Primary carboxylic acid amide</substituent>
    <substituent>Secondary alcohol</substituent>
    <substituent>Secondary carboxylic acid amide</substituent>
    <substituent>Tetracarboxylic acid or derivatives</substituent>
  </classification>
  <salts/>
  <synonyms/>
  <products>
    <product>
      <name>Trulance Immediate Release</name>
      <labeller>Synergy Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>70194-003</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>2017-02-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>3 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA208745</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
  </products>
  <international-brands/>
  <mixtures>
    <mixture>
      <name>Trulance Immediate Release</name>
      <ingredients>Plecanatide</ingredients>
    </mixture>
  </mixtures>
  <packagers/>
  <manufacturers/>
  <prices/>
  <categories>
    <category>
      <category>Amino Acids, Peptides, and Proteins</category>
      <mesh-id>D000602</mesh-id>
    </category>
    <category>
      <category>Chemical Actions and Uses</category>
      <mesh-id>D020164</mesh-id>
    </category>
    <category>
      <category>Enzyme Activators</category>
      <mesh-id>D020536</mesh-id>
    </category>
    <category>
      <category>Hormones</category>
      <mesh-id>D006728</mesh-id>
    </category>
    <category>
      <category>Hormones, Hormone Substitutes, and Hormone Antagonists</category>
      <mesh-id>D006730</mesh-id>
    </category>
    <category>
      <category>Peptide Hormones</category>
      <mesh-id>D036361</mesh-id>
    </category>
    <category>
      <category>Peptides</category>
      <mesh-id>D010455</mesh-id>
    </category>
    <category>
      <category>Pharmacologic Actions</category>
      <mesh-id>D020228</mesh-id>
    </category>
    <category>
      <category>Physiological Effects of Drugs</category>
      <mesh-id>D045505</mesh-id>
    </category>
  </categories>
  <affected-organisms>
    <affected-organism>Humans and other mammals</affected-organism>
  </affected-organisms>
  <dosages>
    <dosage>
      <form>Tablet</form>
      <route>Oral</route>
      <strength>3 mg/1</strength>
    </dosage>
  </dosages>
  <atc-codes/>
  <ahfs-codes/>
  <pdb-entries/>
  <patents/>
  <food-interactions/>
  <drug-interactions/>
  <calculated-properties>
    <property>
      <kind>logP</kind>
      <value>0.64</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logS</kind>
      <value>-4</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>Water Solubility</kind>
      <value>1.65e-01 g/l</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>Molecular Weight</kind>
      <value>1681.89</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Monoisotopic Weight</kind>
      <value>1680.625200237</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>SMILES</kind>
      <value>[H][C@](C)(O)[C@]1([H])N=C(O)[C@]2([H])CSSC[C@]([H])(N=C(O)[C@]([H])(CCC(O)=O)N=C(O)[C@]([H])(CC(O)=O)N=C(O)[C@@]([H])(N)CC(O)=N)C(O)=N[C@@]([H])(CCC(O)=O)C(O)=N[C@@]([H])(CC(C)C)C(O)=N[C@@]([H])(CSSC[C@]([H])(N=C(O)CN=C1O)C(O)=N[C@@]([H])(CC(C)C)C(O)=O)C(O)=N[C@@]([H])(C(C)C)C(O)=N[C@@]([H])(CC(O)=N)C(O)=N[C@@]([H])(C(C)C)C(O)=N[C@@]([H])(C)C(O)=N2</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Formula</kind>
      <value>C65H104N18O26S4</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChI</kind>
      <value>InChI=1S/C65H104N18O26S4/c1-25(2)15-34-55(98)80-41-24-113-110-21-38(58(101)77-37(65(108)109)16-26(3)4)71-44(87)20-69-62(105)50(30(10)84)83-61(104)40(78-51(94)29(9)70-63(106)48(27(5)6)81-57(100)35(18-43(68)86)76-64(107)49(28(7)8)82-60(41)103)23-112-111-22-39(59(102)73-32(53(96)75-34)11-13-45(88)89)79-54(97)33(12-14-46(90)91)72-56(99)36(19-47(92)93)74-52(95)31(66)17-42(67)85/h25-41,48-50,84H,11-24,66H2,1-10H3,(H2,67,85)(H2,68,86)(H,69,105)(H,70,106)(H,71,87)(H,72,99)(H,73,102)(H,74,95)(H,75,96)(H,76,107)(H,77,101)(H,78,94)(H,79,97)(H,80,98)(H,81,100)(H,82,103)(H,83,104)(H,88,89)(H,90,91)(H,92,93)(H,108,109)/t29-,30+,31-,32-,33-,34-,35-,36-,37-,38-,39-,40-,41-,48-,49-,50-/m0/s1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChIKey</kind>
      <value>NSPHQWLKCGGCQR-DLJDZFDSSA-N</value>
      <source>ChemAxon</source>
    </property>
  </calculated-properties>
  <experimental-properties/>
  <external-identifiers>
    <external-identifier>
      <resource>Wikipedia</resource>
      <identifier>Plecanatide</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEMBL</resource>
      <identifier>CHEMBL2103867</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links/>
  <pathways/>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets>
    <target position="1">
      <id>BE0003578</id>
      <name>Guanylate cyclase soluble subunit alpha-2</name>
      <organism>Human</organism>
      <actions>
        <action>agonist</action>
      </actions>
      <references>
        <articles/>
        <textbooks/>
        <links/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="P33402" source="Swiss-Prot">
    <name>Guanylate cyclase soluble subunit alpha-2</name>
    <general-function>Heme binding</general-function>
    <specific-function>Has guanylyl cyclase on binding to the beta-1 subunit.Isoform 2 acts as a negative regulator of guanylyl cyclase activity as it forms non-functional heterodimers with the beta subunits.</specific-function>
    <gene-name>GUCY1A2</gene-name>
    <locus>11q21-q22</locus>
    <cellular-location>Cytoplasm</cellular-location>
    <transmembrane-regions/>
    <signal-regions/>
    <theoretical-pi>7.72</theoretical-pi>
    <molecular-weight>81749.185</molecular-weight>
    <chromosome-location>11</chromosome-location>
    <organism ncbi-taxonomy-id="9606">Human</organism>
    <external-identifiers>
      <external-identifier>
        <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
        <identifier>HGNC:4684</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Gene Database</resource>
        <identifier>X63282</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank Protein Database</resource>
        <identifier>31671</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>P33402</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProt Accession</resource>
        <identifier>GCYA2_HUMAN</identifier>
      </external-identifier>
    </external-identifiers>
    <synonyms>
      <synonym>4.6.1.2</synonym>
      <synonym>GCS-alpha-2</synonym>
      <synonym>GUC1A2</synonym>
      <synonym>GUCSA2</synonym>
    </synonyms>
    <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0006890|Guanylate cyclase soluble subunit alpha-2
MSRRKISSESFSSLGSDYLETSPEEEGECPLSRLCWNGSRSPPGPLEPSPAAAAAAAAPA
PTPAASAAAAAATAGARRVQRRRRVNLDSLGESISRLTAPSPQTIQQTLKRTLQYYEHQV
IGYRDAEKNFHNISNRCSYADHSNKEEIEDVSGILQCTANILGLKFEEIQKRFGEEFFNI
CFHENERVLRAVGGTLQDFFNGFDALLEHIRTSFGKQATLESPSFLCKELPEGTLMLHYF
HPHHIVGFAMLGMIKAAGKKIYRLDVEVEQVANEKLCSDVSNPGNCSCLTFLIKECENTN
IMKNLPQGTSQVPADLRISINTFCRAFPFHLMFDPSMSVLQLGEGLRKQLRCDTHKVLKF
EDCFEIVSPKVNATFERVLLRLSTPFVIRTKPEASGSENKDKVMEVKGQMIHVPESNSIL
FLGSPCVDKLDELMGRGLHLSDIPIHDATRDVILVGEQAKAQDGLKKRMDKLKATLERTH
QALEEEKKKTVDLLYSIFPGDVAQQLWQGQQVQARKFDDVTMLFSDIVGFTAICAQCTPM
QVISMLNELYTRFDHQCGFLDIYKVETIGDAYCVAAGLHRKSLCHAKPIALMALKMMELS
EEVLTPDGRPIQMRIGIHSGSVLAGVVGVRMPRYCLFGNNVTLASKFESGSHPRRINVSP
TTYQLLKREESFTFIPRSREELPDNFPKEIPGICYFLEVRTGPKPPKPSLSSSRIKKVSY
NIGTMFLRETSL</amino-acid-sequence>
    <gene-sequence format="FASTA">&gt;lcl|BSEQ0012487|Guanylate cyclase soluble subunit alpha-2 (GUCY1A2)
ATGTCTCGAAGGAAGATTTCGTCCGAGTCCTTCAGCTCCCTGGGCTCCGACTACCTGGAG
ACCAGCCCGGAGGAGGAGGGGGAGTGCCCCCTGTCTAGGCTCTGCTGGAATGGCAGCCGG
AGCCCGCCCGGGCCGCTGGAGCCCAGCCCGGCCGCAGCTGCCGCTGCCGCCGCCCCGGCC
CCGACCCCGGCTGCTTCTGCCGCCGCCGCCGCTGCCACTGCCGGGGCCAGGAGGGTGCAG
CGCCGGAGGCGGGTCAACCTGGACTCGCTGGGCGAGAGCATCAGCCGCCTGACGGCGCCC
TCGCCTCAGACGATACAGCAGACTCTCAAGAGGACACTGCAGTATTATGAACATCAAGTT
ATTGGTTACAGGGATGCAGAAAAGAATTTCCACAATATCTCTAACAGATGCTCCTATGCA
GACCACTCCAACAAAGAAGAAATTGAAGATGTCTCAGGAATTCTTCAGTGTACTGCTAAT
ATACTCGGTTTGAAGTTTGAGGAAATTCAAAAAAGATTTGGTGAAGAGTTCTTTAATATA
TGCTTTCATGAGAATGAGAGAGTCCTTCGAGCTGTAGGTGGCACTTTGCAGGACTTTTTT
AACGGCTTTGATGCTTTGTTGGAACACATTAGAACTTCTTTTGGAAAACAGGCCACTCTG
GAGTCACCATCTTTCCTATGCAAAGAGCTCCCTGAAGGTACTCTCATGCTCCACTACTTC
CACCCTCACCATATTGTGGGGTTTGCAATGCTGGGGATGATTAAGGCTGCAGGAAAGAAG
ATCTATCGGCTGGATGTGGAAGTGGAACAGGTTGCAAATGAGAAGCTATGCTCTGATGTT
TCAAACCCAGGCAATTGTAGCTGTCTTACTTTCCTTATCAAAGAATGTGAAAATACTAAT
ATCATGAAGAACCTTCCACAGGGAACCTCCCAAGTTCCTGCGGACCTCAGAATTAGCATC
AACACCTTCTGTAGAGCCTTCCCTTTCCACTTGATGTTTGATCCCAGCATGTCAGTCCTT
CAGTTGGGGGAAGGTCTAAGGAAGCAGCTTCGATGTGACACTCACAAAGTGCTCAAGTTT
GAGGACTGCTTCGAGATTGTATCTCCAAAGGTTAATGCCACCTTTGAAAGGGTCCTGCTG
CGACTGTCTACCCCGTTTGTGATTAGAACCAAGCCTGAGGCTTCTGGCTCTGAAAATAAA
GACAAGGTGATGGAAGTCAAAGGACAAATGATCCATGTTCCAGAATCAAATTCCATTTTA
TTTTTGGGCTCTCCATGTGTGGACAAGTTGGATGAACTCATGGGCCGAGGGCTACATCTC
TCAGACATCCCTATCCATGATGCCACCCGAGATGTCATTTTGGTTGGTGAGCAGGCAAAG
GCCCAAGATGGGTTGAAGAAAAGGATGGATAAATTAAAGGCAACTTTAGAAAGAACTCAC
CAGGCCCTGGAAGAAGAGAAAAAGAAGACAGTGGATCTTCTATATTCTATTTTCCCTGGT
GATGTAGCCCAGCAATTATGGCAAGGGCAGCAAGTACAGGCCAGAAAGTTTGATGATGTC
ACCATGCTCTTTTCAGACATTGTTGGCTTCACAGCCATATGTGCCCAGTGTACTCCCATG
CAAGTAATCAGCATGCTGAATGAACTGTACACCAGATTTGACCACCAGTGTGGATTTTTG
GATATTTATAAGGTGGAAACAATAGGTGATGCCTACTGTGTTGCAGCAGGGCTCCACAGA
AAAAGCCTCTGCCATGCTAAACCCATTGCTCTGATGGCCTTGAAGATGATGGAACTTTCA
GAAGAGGTGCTGACACCTGATGGAAGACCGATTCAGATGAGGATAGGAATTCACTCAGGC
TCCGTGCTGGCTGGAGTTGTTGGGGTGCGAATGCCACGTTATTGCCTGTTTGGAAATAAT
GTCACACTGGCAAGCAAATTCGAGTCGGGAAGTCACCCTCGGCGCATCAATGTCAGCCCA
ACCACTTACCAATTATTAAAACGAGAAGAAAGTTTCACATTCATTCCGCGGTCTCGTGAA
GAGCTTCCAGACAACTTTCCAAAGGAAATTCCTGGGATCTGCTATTTCCTGGAGGTAAGG
ACTGGTCCAAAGCCACCAAAGCCTTCTCTTTCTTCGTCGAGAATAAAAAAGGTTTCCTAC
AACATCGGCACCATGTTCCTCCGGGAGACAAGCCTCTGA</gene-sequence>
    <pfams>
      <pfam>
        <identifier>PF00211</identifier>
        <name>Guanylate_cyc</name>
      </pfam>
      <pfam>
        <identifier>PF07700</identifier>
        <name>HNOB</name>
      </pfam>
      <pfam>
        <identifier>PF07701</identifier>
        <name>HNOBA</name>
      </pfam>
    </pfams>
    <go-classifiers>
      <go-classifier>
        <category>component</category>
        <description>guanylate cyclase complex, soluble</description>
      </go-classifier>
      <go-classifier>
        <category>component</category>
        <description>plasma membrane</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>guanylate cyclase activity</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>heme binding</description>
      </go-classifier>
      <go-classifier>
        <category>function</category>
        <description>GTP binding</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>intracellular signal transduction</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>positive regulation of cGMP biosynthetic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>cGMP biosynthetic process</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>signal transduction</description>
      </go-classifier>
      <go-classifier>
        <category>process</category>
        <description>blood coagulation</description>
      </go-classifier>
    </go-classifiers>
  </polypeptide>
    </target>
  </targets>
  <enzymes/>
  <carriers/>
  <transporters/>
</drug>
